Fundraising Fox
/Companies
Sign in

Pearl Bio

Stamford, US · Founded 2020 · Delaware corporation · 10 employees on LinkedIn · 2 known investors

Find your way into Pearl Bio

Sign up to see every warm intro you have to Pearl Bio

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Pearl Bio team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Pearl Bio develops technologies for genome engineering, ribosome engineering, and biomanufacturing to enable production of novel proteins, chemicals, and materials for biotechnology and medicine.

BiotechDeep TechNew Materials

Founders & leadership

Pearl Bio was founded in 2020 by Farren Isaacs, Michael Jewett, and Amy Cayne Schwartz.

FIFarren Isaacs
Farren IsaacsFounder
MJMichael Jewett
Michael JewettFounder
ACAmy Cayne Schwartz
Amy Cayne SchwartzFounderAmy Cayne Schwartz practiced corporate law at major Wall Street firms serving Fortune 500 clients, led Genome Project-write as President and General Counsel overseeing legal matters and technical working groups, and holds a B.A. from the University of Pennsylvania, a J.D. from Fordham School of Law, and a certification in biomanufacturing from MIT; she co-founded Pearl Bio where she serves as COO, CBO & General Counsel.
MG
Merton GollaherExecutive

Board

GCGeorge Church
George ChurchScience Advisor
JRJesse Rinehart
Jesse RinehartScience Advisor

Investors · 2

The Engine VenturesreportedCambridge

How we know: open dataset · 5k.vc investor directory · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$4.1M disclosed across 1 round · 2021

▶$4.1MraisedOct 2021 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Merton GollaherExecutive Officer
  • Farren IsaacsExecutive Officer, Director
  • Michael JewettExecutive Officer, Director
Offering amount
$5M
Amount sold
$4.1M
First sale
Aug 2021
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 5

Pillar BiosciencesPillar Biosciences develops kitted next-generation sequencing (NGS) panels and its SLIMamp single-tube library preparation technology for clinical and research laboratories, focused on cancer diagnostics. Its oncoReveal portfolio of RUO and IVD oncology panels covers solid tumors, hematologic cancers, and liquid biopsy, aiming to deliver faster, lower-cost genomic testing for precision medicine.
ARTBIOARTBIO develops alpha radioligand therapies (ARTs) for cancer treatment, designing target-and-molecule combinations intended to kill tumors while sparing healthy tissue. The company covers the design, manufacture, and distribution of its therapies and builds on radiation research from the University of Oslo and Norway's Radium Hospital.
Pattern BiosciencePattern develops rapid antibiotic susceptibility and infection diagnostics using single-cell microbiology, which reads the metabolic patterns of individual bacterial cells to deliver ID/AST results in hours without culture steps. Its phenotypic testing targets common infection sites to support faster, more focused antibiotic treatment in hospitals and combat antibiotic resistance.
Pear BioPear Bio delivers precision medicine tests and therapeutics for patients with hard-to-treat cancers by creating personalized treatment predictions from tumor biopsies and developing novel targeted therapies.
Parallel BioParallel Bio develops human immune organoids and computational tools to predict drug efficacy across diverse patient populations, replacing animal testing in drug discovery. The company aims to accelerate pharmaceutical development and reduce clinical trial failure rates through human-first biological prediction models.

Companies working in the same space as Pearl Bio.

Non-dilutive funding · 2 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Science FoundationPhase I2023$274.5K
Department of DefenseOffice of the Secretary of DefensePhase ISTTR2023$250K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

Pearl Bio Secures Breakthrough IP for Multi-Functionalized Biologics - BioSpacebiospace.com · Jun 2023About Us | Pearl Biopearlbio.com · Jan 2022

Frequently asked questions

What does Pearl Bio do?
Pearl Bio develops technologies for genome engineering, ribosome engineering, and biomanufacturing to enable production of novel proteins, chemicals, and materials for biotechnology and medicine.
Who founded Pearl Bio?
Pearl Bio was founded by Farren Isaacs, Michael Jewett, Amy Cayne Schwartz in 2020.
Who are Pearl Bio's investors?
Pearl Bio's investors include Khosla Ventures, The Engine Ventures.
How much funding has Pearl Bio raised?
Pearl Bio has disclosed $4.1M raised across 1 round.
Where is Pearl Bio headquartered?
Pearl Bio is headquartered in Stamford, US.